Ordinary Adjustment | Solactive China Biotech v2 Index | Effective Date 15th July 2024
Solactive China Biotech v2 Index:
In the ordinary adjustment, the following composition will be implemented effective open 15th July 2024:
JIANGSU HENGRUI MEDICINE CO LTD CLASS A |
WUXI APPTEC CO LTD-A |
INNOVENT BIOLOGICS INC |
WUXI BIOLOGICS CAYMAN INC |
SHANGHAI RAAS BLOOD PRODUC-A |
SINO BIOPHARMACEUTICAL LTD ORD |
BEIJING TIANTAN BIOLOGICAL-A |
SHENYANG XINGQI PHARMACEUT-A |
AKESO INC |
HANSOH PHARMACEUTICAL GROUP CO |
GAN & LEE PHARMACEUTICALS -A |
WALVAX BIOTECHNOLOGY CO-A |
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD |
HUALAN BIOLOGICAL ENGINEER-A |
HUTCHMED CHINA LTD |
SHANGHAI ALLIST PHARMACEUTICALS CO LTD |
LIVZON PHARMACEUTICAL GROU-A |
SHANGHAI JUNSHI BIOSCIENCE |
MGI TECH CO LTD |
HUBEI JUMPCAN PHARMACEUT-A |
HYGEIA HEALTHCARE HOLDINGS CO LTD |
GENSCRIPT BIOTECH CORP |
BGI GENOMICS CO LTD-A |
CHINA MEDICAL SYSTEM HOLDINGS LTD |
SHENZHEN KANGTAI BIOLOGICA-A |
APELOA PHARMACEUTICAL CO-A |
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD |
SKB BIO-B ORD H |
REMEGEN CO LTD-A |
SICHUAN BIOKIN PHARMACEUTICAL CO LTD |